Regen BioPharma Inc (RGBPP) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
4700 SPRING ST #304 LA MESA, CA 91942 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 MRQ | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 124 | 121 | 51 | 727 | 8 | ||||
| Cash and cash equivalents | 124 | 121 | 51 | 727 | 8 | ||||
| Receivables | 12 | 254 | 219 | 103 | 71 | ||||
| Prepaid expense | 5 | 10 | 21 | 48 | 0 | 0 | |||
| Other undisclosed current assets | 10 | 0 | |||||||
| Total current assets: | 142 | 131 | 336 | 994 | 103 | 79 | |||
| Noncurrent Assets | |||||||||
| Other undisclosed noncurrent assets | 18 | 223 | 223 | 218 | 20 | 20 | |||
| Total noncurrent assets: | 18 | 223 | 223 | 218 | 20 | 20 | |||
| TOTAL ASSETS: | 160 | 354 | 559 | 1,212 | 123 | 99 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 48 | 34 | 1,267 | 1,267 | 1,189 | 972 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 4 | 4 | 4 | ||
| Accounts payable | 44 | 30 | 29 | 91 | 110 | 92 | |||
| Accrued liabilities | 4 | 4 | |||||||
| Other undisclosed accounts payable and accrued liabilities | 1,238 | 1,171 | 1,075 | 876 | |||||
| Debt | 50 | 97 | 1 | 10 | 1 | ||||
| Due to related parties | ✕ | ✕ | ✕ | 1 | 0 | 62 | 89 | ||
| Other undisclosed current liabilities | 5,148 | 5,177 | 7,327 | 13,421 | 6,206 | 9,942 | |||
| Total current liabilities: | 5,247 | 5,308 | 8,595 | 14,698 | 7,458 | 11,003 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 154 | 150 | |||||||
| Long-term debt, excluding current maturities | 154 | 150 | |||||||
| Other undisclosed noncurrent liabilities | 5 | ||||||||
| Total noncurrent liabilities: | 154 | 150 | 5 | ||||||
| Total liabilities: | 5,401 | 5,458 | 8,595 | 14,698 | 7,458 | 11,008 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (5,241) | (5,104) | (8,036) | (13,533) | (7,335) | (10,909) | |||
| Common stock | 0 | 0 | 503 | 435 | 160 | 60 | |||
| Additional paid in capital | 14,120 | 13,908 | 11,581 | 8,644 | 8,314 | 8,262 | |||
| Accumulated deficit | (20,099) | (19,749) | (20,905) | (23,349) | (16,584) | (19,998) | |||
| Other additional capital | 736 | 736 | 736 | 736 | 732 | 729 | |||
| Other undisclosed equity, attributable to parent | 0 | 0 | 48 | 43 | 39 | ||||
| Other undisclosed equity | 48 | ||||||||
| Total equity: | (5,241) | (5,104) | (8,036) | (13,486) | (7,335) | (10,909) | |||
| TOTAL LIABILITIES AND EQUITY: | 160 | 354 | 559 | 1,212 | 123 | 99 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 TTM | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 127 | 127 | 126 | 61 | 110 | 110 | ||
| Cost of revenue | (294) | (606) | (389) | (216) | (56) | (202) | ||
| Gross profit: | (168) | (480) | (263) | (155) | 54 | (92) | ||
| Operating expenses | (288) | (317) | (186) | (156) | (263) | (664) | ||
| Other undisclosed operating income | 110 | 110 | 110 | 110 | ||||
| Operating loss: | (346) | (687) | (340) | (201) | (209) | (757) | ||
| Nonoperating income (expense) | (227) | 1,843 | 1 | |||||
| Investment income, nonoperating | 1 | |||||||
| Interest and debt expense | (0) | 1 | (234) | (292) | (333) | (295) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 1,843 | |||||||
| Income (loss) from continuing operations: | 1,270 | 1,158 | (573) | (492) | (543) | (1,051) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (573) | (492) | (543) | (1,051) | |
| Other undisclosed net income | 54 | |||||||
| Net income (loss): | 1,324 | 1,158 | (573) | (492) | (543) | (1,051) | ||
| Other undisclosed net income (loss) attributable to parent | (2,153) | (1) | 3,017 | (6,273) | 3,957 | (1,573) | ||
| Net income (loss) attributable to parent: | (829) | 1,157 | 2,444 | (6,765) | 3,414 | (2,623) | ||
| Other undisclosed net income (loss) available to common stockholders, basic | 45 | (133) | (216) | (683) | ||||
| Net income (loss) available to common stockholders, diluted: | (784) | 1,024 | 2,227 | (6,765) | 2,732 | (2,623) | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 TTM | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 1,324 | 1,158 | (573) | (492) | (543) | (1,051) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 1,324 | 1,158 | (573) | (492) | (543) | (1,051) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.